Eli Lilly & Co (DE:LLY)
XETRA:LLY
Ly3841136, Eloralintide
Renal Insufficiency, Renal Impairment, Kidney Disease, Kidney Failure, Chronic, Renal Insufficiency Chronic, End Stage Kidney Disease
Phase I
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Feb 17, 2026
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Eli Lilly & Co (LLY) have in its pipeline
LLY is currently developing the following drugs: Mirikizumab - Intravenous, Mirikizumab - Subcutaneous, Ly4395089, Ly3074828, Mirikizumab - Intravenous, Mirikizumab - Subcutaneous, Ly4395089, Ly3074828, Mirikizumab, Ly3074828. These drug candidates are in various stages of clinical development as the company works toward FDA approval.